|
 |
| home > epc > summer 2003 > an interview with john kolthammer, chief executive officer of the institute of clinical research |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
You joined ICR last year as CEO, what was your background and motivation for taking the role?
I've worked in the drug and NHS service for about 40 years, including three hospital appointments and four CROs but most of my time has been spent within the pharmaceutical industry as Head of Toxicology, Head of Regulatory Affairs and the Managing Director of an Italian drug company. I then moved into training and enjoyed the role. The ICR position was then suggested and I believed I could apply my management and financial skills to the organisation, although my career path had not included being a CRA.
How do you plan to take ICR forward as a business?
I see my role as developing ICR as a properly run business enterprise, with good financial control and sensible development plans that will benefit the members. I'm not interested in gradual change, we have to step up into a new phase and develop ICR as a professional body, particularly with respect to clinical science. I think we've started to achieve this reasonably well and this year will be another step forward. ICR now has employees, therefore the staff/company perspective has changed and the organisation has to reflect that difference. We're now in a much more conventional commercial environment and that is something I'm very comfortable with.
ICR has seen considerable membership growth over the last 25 years, what factors have contributed to this?
Clinical research professionals are now recognised as major players in drug development. It has been slow in coming because in the early days drug development was very physician orientated, we didn't have 'clinical research' professionals. Physicians are still a critical part of the process because of their skills and knowledge but a need has evolved for a group of individuals who are not necessarily medically qualified and we need to keep emphasising their role and responsibilities.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Julia Lloyd-Parks, Editor of EPC and Senior Consultant at Technomark Consulting Services
The Institute of Clinical Research (ICR) held its Spring meeting and AGM in Manchester this April. Held atG-MEX and the Manchester International Convention Centre, there were nearly 170 exhibition stands and about 1,100 delegates. 2003 marks the 25th anniversary of ICR, and after the AGM a presentation was given reflecting changes in the clinical research field. ICR has over 5,000 members working in pharmaceutical, medical device, diagnostics companies, CROs, the NHS and academia.
In 2002 ICR appointed John Kolthammer to the new role of Chief Executive Officer, and during the meeting I interviewed him to find out more about development at ICR.
|
|
|
|
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
